

Amendment to the Claims

This listing of the claims replaces all prior versions and listings of the claims in the application.

Listing of the Claims:

1-66. (Canceled)

67. (Currently Amended) A method of treating an ACE2 decreased state in a mammal, wherein the ACE2 decreased state is cardiovascular disease, renal failure, and/or lung disease, comprising ~~identifying an ACE2 decreased state in a mammal having hypertension, congestive heart failure, chronic heart failure, acute heart failure, myocardial infarction, arteriosclerosis, a~~ cardiovascular disease, renal failure, and/or lung disease, and administering to the mammal an therapeutically effective amount of an a mammalian ACE2 polypeptide, wherein the ACE2 decreased state cardiovascular disease, renal failure, and/or lung disease is treated.

68. (Previously Presented) The method of claim 67, wherein the mammal is a human.

69-72. (Canceled)

73. (Previously Presented) The method of claim 67, further comprising administering an ACE inhibitor to the mammal.

74-99. (Canceled)

100. (Currently Amended) The method of claim 67, wherein ~~the mammal has a lung disease~~ is treated.

101. (Previously Presented) The method of claim 100, wherein the lung disease is acute respiratory distress syndrome.

102. (Previously Presented) The method of claim 100, wherein the lung disease is lung cancer.

103. (Canceled)

104. (Previously Presented) The method of claim 100, wherein the lung disease is chronic obstructive pulmonary disease, pneumonia, asthma, chronic bronchitis, pulmonary emphysema, cystic fibrosis, interstitial lung disease, primary pulmonary hypertension, pulmonary embolism, pulmonary sacrodosis, tuberculosis, or lung edema.

105. (Previously Presented) The method of claim 67, wherein the ACE2 polypeptide is a mouse ACE2 polypeptide.

106. (Previously Presented) The method of claim 67, wherein the ACE2 polypeptide is a rat ACE2 polypeptide.

107. (Previously Presented) The method of claim 67, wherein the ACE2 polypeptide is a human ACE2 polypeptide.

108-109. (Canceled)

110. (Currently Amended) The method of claim ~~[[108]]~~100, wherein the lung disease is pulmonary hypertension.

111-115. (Canceled)

116. (Currently Amended) ~~A method of treating a cardiovascular disease comprising administering to a mammal having a cardiovascular disease a therapeutically effective amount of an ACE2 polypeptide~~The method of claim 67, wherein the cardiovascular disease is treated.

117. (Previously Presented) The method of claim 116, wherein the cardiovascular disease is chronic heart failure.

118. (Previously Presented) The method of claim 116, wherein the cardiovascular disease is myocardial infarction.

119. (Previously Presented) The method of claim 116, wherein the cardiovascular disease is hypertension.

120. (Previously Presented) The method of claim 116, wherein the cardiovascular disease is acute heart failure, left ventricular hypertrophy, or cardiomyopathy.

121-124. (Canceled)

125. (Currently Amended) ~~A method of treating a kidney disease comprising administering to a mammal having a kidney disease a therapeutically effective amount of an ACE2 polypeptide~~The method of claim 67, wherein the kidney disease is treated.

126-134. (Canceled)